Nanomedicine News

RSS

NSF Awards UCLA $1 Million Grant for Quantification and Automated Characterization of Nanoparticles

Researchers at the UCLA Henry Samueli School of Engineering and Applied Science and California NanoSystems Institute (CNSI) have won a $1 million, three-year grant from the National Science Foundation for on-site and ubiquitous quantification and automated characterization of nanoparticles found in homes, workplaces and the environment.

From University of California, Los Angeles 18 Sep 2015

Novel Technique for Real-Time Observation of Bloodstream Protein Interactions with Nanoparticles

Technique developed by NUS-led team provides more precise understanding of how proteins in the bloodstream bind to nanoparticles, paving the way for better design of nanomedicines

18 Sep 2015

Researchers Secure €3.3 Million Funding to Develop Enhanced Nanoparticle Treatment Programme for Pancreatic Cancer

Researchers at the University at Buffalo, Dublin City University and Queen’s University Belfast have secured over €3.3 million to develop an enhanced treatment programme for pancreatic cancer, the fourth leading cause of cancer deaths in the world.

16 Sep 2015

Onxeo Seeks Patent for Livatag Liver Cancer Orphan Oncology Product

Onxeo S.A., an innovative biopharmaceutical company specialized in the development of drugs for orphan oncology diseases, today announced that it has filed an international patent application to protect the overall compound related to its primary liver cancer orphan oncology product Livatag®. The patent application has been filed in the US and Europe and will be expanded to include other regions, including the Asian territories, under the patent review procedure. If granted, this patent would protect Livatag® until 2036.

16 Sep 2015

Novavax RSV F-Protein Recombinant Nanoparticle Vaccine Candidate Highly Immunogenic in Preclinical Maternal Immunization Model

Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) was shown to be highly immunogenic in a guinea pig model of maternal immunization. The preclinical study was published in the journal Vaccine.

From Novavax Inc. 16 Sep 2015

Global Nanomedicine Market Estimated to Grow at 12.3% CAGR During 2013 to 2019

Transparency Market Research (TMR) has recently published a market study based on the global nanomedicine market, estimating the market to grow at a healthy CAGR of 12.3% during the period from 2013 to 2019 in order to reach US$177.60 billion by 2019.The study, titled "Nanomedicine Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019", reports that the global nanomedicine market stood at US$78.54 billion in 2012.

16 Sep 2015

Kettering to Acquire High-Resolution TEM for Nanoscale Imaging with NSF-MRI Grant

Dr. Ronald J. Tackett, faculty member in the Kettering University department of Physics, along with collaborators from multiple disciplines across campus have been awarded a National Science Foundation - Major Research Instrumentation (NSF-MRI) grant for $452,000. The grant will allow Tackett to acquire a high-resolution transmission electron microscope (TEM) with energy dispersive spectroscopy capabilities to support ongoing investigations and potentially advance materials science and nanotechnology research and teaching at Kettering.

15 Sep 2015

CeloNova Commences Enrolment in Nano-Coated COBRA PzF Coronary Stent System Study

CeloNova BioSciences, Inc. (CN) has announced that it enrolled the first patient in its multicenter e-COBRA clinical study in France. This prospective registry will further assess the safety and efficacy of the novel COBRA PzF coronary stent system in real world and complex patients with heart disease.

15 Sep 2015

NantWorks Enters Agreement with Amgen to Further Develop AMG 337 Cancer Therapeutic

NantPharma, LLC, a subsidiary of NantWorks, LLC, having recently acquired the pharmaceutical product nant-paclitaxel (formerly Cynviloq), today announced that it has entered into an exclusive license agreement with Amgen Inc. for AMG 337. Under the agreement, NantPharma acquired the exclusive rights to develop and commercialize worldwide, excluding Japan, Russia and certain other Central Asian countries, AMG 337, a phase 2 small molecule inhibitor of the cell surface enzyme c-Met, an important target for cancer therapy.

15 Sep 2015

US-Ireland Partnership to Focus on Nanomedicine for Treatment of Pancreatic Cancer

A US-Ireland partnership involving researchers at Queen’s University Belfast has been awarded £2.9m to develop new treatments for pancreatic cancer, which is the fifth most common cause of cancer deaths in the UK.

15 Sep 2015

Nanomedicine News

NSF Awards UCLA $1 Million Grant for Quantification and Automated Characterization of Nanoparticles

Novel Technique for Real-Time Observation of Bloodstream Protein Interactions with Nanoparticles

Researchers Secure €3.3 Million Funding to Develop Enhanced Nanoparticle Treatment Programme for Pancreatic Cancer

Onxeo Seeks Patent for Livatag Liver Cancer Orphan Oncology Product

Novavax RSV F-Protein Recombinant Nanoparticle Vaccine Candidate Highly Immunogenic in Preclinical Maternal Immunization Model

Global Nanomedicine Market Estimated to Grow at 12.3% CAGR During 2013 to 2019

Kettering to Acquire High-Resolution TEM for Nanoscale Imaging with NSF-MRI Grant

CeloNova Commences Enrolment in Nano-Coated COBRA PzF Coronary Stent System Study

NantWorks Enters Agreement with Amgen to Further Develop AMG 337 Cancer Therapeutic

US-Ireland Partnership to Focus on Nanomedicine for Treatment of Pancreatic Cancer

Laser-Induced Graphene for Printable and Biomedical Applications

Enhanced Antibacterial Polylactic Acid-Curcumin Nanofibers for Wound Dressings

Co-Solvent-Driven Laser Assembly of Gold Nanorods

Cigarette Waste as a Source for Sustainable Supercapacitors

Novel Technique Dramatically Increases Graphene's Elasticity

Breaking Barriers in Thin-Film Deposition with ATLANT 3D’s DALP Technology

Overcoming Nanogold Production Challenges

Electrospinning and the Future of Nanotechnology

Sponsored Content

Unlocking Material Behavior at the Microscale Using Nanoindentation

Utilizing Back-Gate Voltage Biases for 2D Materials

Resistivity Metrology for Sputtered ITO Thin Films

How Plasma Cleaning Technology Tackles Hydrocarbon Contamination